1. Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Introduction: Immunotherapy in RCC

4. IMmotion150: Phase 2 Study of Atezolizumab With or Without Bevacizumab vs Sunitinib in mRCC

5. IMmotion150: PFS Outcomes

6. IMmotion150 Results

7. Outcomes of PD-1/PD-L1 Responders Discontinuing Due to irAEs

8. Effect of Nivolumab on TGR

9. Activity of Nivolumab in Patients With Brain Metastases

10. Selecting Therapy in Previously Treated Advanced RCC

11. Factors to Consider When Selecting Second-Line Therapy in Advanced RCC

12. Clinical Trials in First-Line Advanced RCC

13. Recognizing and Managing irAEs

14. Concluding Remarks

15. Abbreviations

16. Abbreviations (cont)